Mumbai, June 9 -- Co-developed with global oncology leader BeOne Medicines, zanubrutinib will be marketed under the brand name Brukinsa. It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for five types of B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).

Globally, Brukinsa is approved in over 70 countries, backed by robust clinical evidence from pivotal trials such as Alpine, Aspen, and Sequoia. The drug has shown a strong safety profile, high response rates, and durable disease control.

With one Indian diagnosed with blood cancer every five mi...